PCA-2 (Purkinje Cell Antibody 2) Line Assay und Purkinje Line Assay



  1. S. Rauer. Paraneoplastische Neurologische Syndrome. Fortschr Neurol Psychiatr. 2011;79(1):51-8; quiz 59-61. Review.
  2. Oliver Stich, Sven Jarius, Christiane Rasiah, Raymond Volz und Sebastian Rauer. Recombinant immunoblot for assessment of intrathecally synthesized paraneoplastic antineural antibodies in cerebrospinal fluid from patients with paraneoplastic neurological syndromes. Clin Chem Lab Med 2008;46(12):1793-1795.
  3. Lisa M. DeAngelis and Jerome B. Posner. Neurologic Complications of Cancer. Oxford University Press 2008 Second Edition
  4. F. Graus, J.Y. Delattre, J. C. Antoine, J. Dalmau, B. Giometto, W. Grishold, J. Honnorat, P. Sillevis Smitt, Ch. Vedeler, J. J. G. M. Verschuuren, A. Vincent, R. Voltz, for the Paraneoplastic Neurological Syndrome Euronetwork. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135-1140.
  5. Voltz R. Paraneoplastische neurologische Autoimmunerkrankungen. Nervenarzt 2002;73:909 – 929.
  6. Honnorat J., Antoine J.C., Derrington E., Aguqra M., Belin M.F. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J.Neurol.Neurosurg.Psychiatry 1996;61(3): 270-8.
  7. Sillevis-Smitt P., Manley G., Dalmau J., Posner J.B.Pitfalls in the diagnosis of autoantibodies associated with paraneoplastic neurologic disease. Neurology 1996;46:1739-1741.
  8. Moll J.W., Antoine J.C., Brashear H.R. et al. Guidelines on the detection of paraneoplastic anti-neuronal-specific antibodies: report from the Workshop to the fourth Meeting of the International Society of Neuro-Immunology on paraneoplastic neurological disease. Neurology 1995;45:1937-1941.
  9. Moll J.W., Vecht C.J. Immune diagnosis of paraneoplastic neurological diseases. Clin. Neurol. Neurosurg.1995;97: 711-81.
  10. Dalmau J., Posner J.B. Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity.Neurology 1994;44:2241-2246.
  1. Nobile-Orazio E., Gallia F., Terenghi F., Allaria S., Giannotta C., Carpo M. How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? Journal of the Neurological Sciences 2008; 266: 156-163.
  2. Quarles R.H. Myelin-associated glycoprotein (MAG): past, present and beyond. Journal of Neurochemistry. 2007; 100: 1431-1448.
  3. Kuijf M.L., Eurelings M., Tio-Gillen A.P., van Doorn P.A., van den Berg L.H., Hooijkaas H., Stork J., Notermans N.C. and Jacobs B.C.. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 2007; 73: 688-695.
  4. Steck A. Auto-antibody tests in peripheral neuropathies: pros and cons. J Neurol 2000; 247: 423-428.
  5. Vital A., Vital C., Julien J., Baquey A., Steck A.J. Polyneuropathy associated with IgM monoclonal gammopathy. Acta Neuropathol 1989; 79: 160-167.
  1. L. Sabater PhD, M. Titulaer MD, A. Saiz MD, J. Verschuuren MD, A. O. Güre MD, and F. Graus MD, Neurology, 2008; 70: 924-928.

  1. Michael P. Malter, Christoph Helmstaedter, Horst Urbach, Angela Vincent and Christian G. Bien. Antibodies to Glutamic Decarboxylase Define a Form of Limbic Encephalitis. Ann Neurol 2010;67:470-478.

ravo Diagnostika GmbH, Oltmannsstr. 5, D-79100 Freiburg,
Telefon + 49 (0)761 40 74 88, Fax +49 (0)761 40 74 77, email